Alpine Immune Sciences, Inc., a Seattle, WA-based biotechnology company developing an immune system modulation platform, closed a $48m Series A financing round.
The round was led by OrbiMed Advisors, with participation from Frazier Healthcare Partners and Alpine BioVentures.
In conjunction with the funding, Mitchell H. Gold, M.D., Managing Partner at Alpine BioVentures, will join as AIS’ Executive Chairman and acting Chief Executive Officer. Jay Venkatesan, M.D., Managing Partner at Alpine BioVentures, will be President and a member of the board of directors. They will be joined on the board of directors by Jamie Topper, M.D., Ph.D., Managing General Partner of Frazier Healthcare Partner’s Life Sciences team and Peter Thompson, M.D., Private Equity Partner with OrbiMed Advisors.
Founded in 2015 and seed funded by Alpine BioVentures, Alpine Immune Sciences uses its proprietary variant immunoglobulin domain (vIgD™) platform technology – designed to interact with multiple targets simultaneously in the immune synapse using a single molecule – to develop novel protein‐based immunotherapies. The company has also developed transmembrane immunomodulatory protein (TIP™) technology, based on vIgD™, for direct applications with engineered cellular therapies, potentially improving their efficacy and persistence.
In October of 2015, AIS signed a worldwide research and license agreement with Kite Pharma, Inc. worth up to $530 million allowing Kite access to certain targets developed using the AIS TIP™ platform.